Patents by Inventor Yingxia Wen

Yingxia Wen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240300994
    Abstract: Methods for purifying RNA from a sample, comprising one or more steps of tangential flow filtration, hydroxyapatite chromatography, core bead flow-through chromatography, or any combinations thereof. These techniques are useful individually, but show very high efficiency when used in combination, or when performed in particular orders. The methods can purify RNA in a highly efficient manner without unduly compromising potency or stability, to provide compositions in which RNA is substantially cleared of contaminants. Moreover, they can be performed without the need for organic solvents.
    Type: Application
    Filed: May 15, 2024
    Publication date: September 12, 2024
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Francesco BERLANDA SCORZA, Yingxia WEN, Andrew GEALL, Frederick PORTER
  • Patent number: 12018044
    Abstract: Methods for purifying RNA from a sample, comprising one or more steps of tangential flow filtration, hydroxyapatite chromatography, core bead flow-through chromatography, or any combinations thereof. These techniques are useful individually, but show very high efficiency when used in combination, or when performed in particular orders. The methods can purify RNA in a highly efficient manner without unduly compromising potency or stability, to provide compositions in which RNA is substantially cleared of contaminants. Moreover, they can be performed without the need for organic solvents.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: June 25, 2024
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Francesco Berlanda Scorza, Yingxia Wen, Andrew Geall, Frederick Porter
  • Publication number: 20240024455
    Abstract: The present disclosure relates to multicistronic RNA vaccines and uses thereof. The present disclosure also relates to multicistronic conventional mRNA vaccines and uses thereof.
    Type: Application
    Filed: December 2, 2021
    Publication date: January 25, 2024
    Inventors: Pirada ALLEN, Ivna DE SOUZA, Yingxia WEN, Sukhmani BEDI, Cheng CHANG
  • Publication number: 20240024460
    Abstract: The present disclosure relates to self-replicating RNA encoding an antigen from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and uses thereof. Specifically, the disclosure provides a self-replicating RNA or a monocistronic self-replicating RNA comprising a nucleotide sequence encoding an antigen operably linked to a subgenomic promoter, wherein the antigen is from SARS-CoV-2, and wherein the antigen is a Spike (S) protein or a nucleocapsid (N) protein.
    Type: Application
    Filed: December 2, 2021
    Publication date: January 25, 2024
    Inventors: Pirada ALLEN, Ivna DE SOUZA, Yingxia WEN, Cheng CHANG, CHANGKEUN Lee
  • Publication number: 20220106364
    Abstract: An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying such complexes, and subsequent uses of such complexes in immunogenic compositions and vaccines, are also provided.
    Type: Application
    Filed: December 15, 2021
    Publication date: April 7, 2022
    Inventors: Andrea CARFI, Yingxia WEN
  • Patent number: 11249088
    Abstract: The present application discloses stability-indicating potency assays for influenza vaccines.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: February 15, 2022
    Assignee: Seqirus UK Limited
    Inventors: Yingxia Wen, Ethan Settembre, Zihao Wang
  • Patent number: 11155572
    Abstract: Methods for purifying RNA from a sample, comprising one or more steps of tangential flow filtration, hydroxyapatite chromatography, core bead flow-through chromatography, or any combinations thereof. These techniques are useful individually, but show very high efficiency when used in combination, or when performed in particular orders. The methods can purify RNA in a highly efficient manner without unduly compromising potency or stability, to provide compositions in which RNA is substantially cleared of contaminants. Moreover, they can be performed without the need for organic solvents.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 26, 2021
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Francesco Berlanda Scorza, Yingxia Wen, Andrew Geall, Frederick Porter
  • Publication number: 20210214388
    Abstract: Methods for purifying RNA from a sample, comprising one or more steps of tangential flow filtration, hydroxyapatite chromatography, core bead flow-through chromatography, or any combinations thereof. These techniques are useful individually, but show very high efficiency when used in combination, or when performed in particular orders. The methods can purify RNA in a highly efficient manner without unduly compromising potency or stability, to provide compositions in which RNA is substantially cleared of contaminants. Moreover, they can be performed without the need for organic solvents.
    Type: Application
    Filed: January 25, 2021
    Publication date: July 15, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Francesco BERLANDA SCORZA, Yingxia WEN, Andrew GEALL, Frederick PORTER
  • Publication number: 20200200764
    Abstract: The present application discloses stability-indicating potency assays for influenza vaccines.
    Type: Application
    Filed: July 29, 2019
    Publication date: June 25, 2020
    Inventors: Yingxia WEN, Ethan SETTEMBRE, Zihao WANG
  • Patent number: 10414802
    Abstract: This invention relates to cytomegalovirus (CMV) proteins suitable for vaccine uses. Provided herein are mammalian host cells, in particular CHO cells, in which the sequence(s) encoding CMV proteins gH, gL, pUL128, pUL130, pUL131 (or a complex-forming fragment thereof) are stably integrated into the genome.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: September 17, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Andrea Carfi, Claudio Ciferri, Irmgard Hofmann, Holger Laux, Anders Lilja, Yingxia Wen
  • Patent number: 10416171
    Abstract: The present application discloses stability-indicating potency assays for influenza vaccines.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: September 17, 2019
    Assignee: Seqirus UK Limited
    Inventors: Yingxia Wen, Ethan Settembre, Zihao Wang
  • Publication number: 20190211064
    Abstract: An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying such complexes, and subsequent uses of such complexes in immunogenic compositions and vaccines, are also provided.
    Type: Application
    Filed: March 25, 2019
    Publication date: July 11, 2019
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Andrea CARFI, Yingxia WEN
  • Patent number: 10287322
    Abstract: An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying such complexes, and subsequent uses of such complexes in immunogenic compositions and vaccines, are also provided.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: May 14, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Andrea Carfi, Yingxia Wen
  • Publication number: 20180196061
    Abstract: The present application discloses stability-indicating potency assays for influenza vaccines.
    Type: Application
    Filed: July 7, 2016
    Publication date: July 12, 2018
    Inventors: Yingxia WEN, Ethan SETTEMBRE, Zihao WANG
  • Publication number: 20170362278
    Abstract: This invention relates to cytomegalovirus (CMV) proteins suitable for vaccine uses. Provided herein are mammalian host cells, in particular CHO cells, in which the sequence(s) encoding CMV proteins gH, gL, pUL128, pUL130, pUL131 (or a complex-forming fragment thereof) are stably integrated into the genome.
    Type: Application
    Filed: October 29, 2015
    Publication date: December 21, 2017
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Andrea CARFI, Claudio CIFERRI, Irmgard HOFMANN, Holger LAUX, Anders LILJA, Yingxia WEN
  • Publication number: 20170320916
    Abstract: An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying such complexes, and subsequent uses of such complexes in immunogenic compositions and vaccines, are also provided.
    Type: Application
    Filed: May 16, 2017
    Publication date: November 9, 2017
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Andrea CARFI, Yingxia Wen
  • Patent number: 9683022
    Abstract: An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying such complexes, and subsequent uses of such complexes in immunogenic compositions and vaccines, are also provided.
    Type: Grant
    Filed: June 29, 2013
    Date of Patent: June 20, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Andrea Carfi, Yingxia Wen
  • Publication number: 20160159864
    Abstract: This disclosure provides an isolated human cytomegalovirus (HCMV) membrane protein complex, wherein said complex comprises gH, gL and at least one more HCMV glycoprotein. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. The disclosure also provides processes for expressing and purifying said complexes, and subsequent uses of said complexes in immunogenic compositions and vaccines.
    Type: Application
    Filed: June 29, 2013
    Publication date: June 9, 2016
    Inventors: Andrea Carfi, Yingxia Wen
  • Publication number: 20160024139
    Abstract: Methods for purifying RNA from a sample, comprising one or more steps of tangential flow filtration, hydroxyapatite chromatography, core bead flow-through chromatography, or any combinations thereof. These techniques are useful individually, but show very high efficiency when used in combination, or when performed in particular orders. The methods can purify RNA in a highly efficient manner without unduly compromising potency or stability, to provide compositions in which RNA is substantially cleared of contaminants. Moreover, they can be performed without the need for organic solvents.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 28, 2016
    Inventors: Francesco BERLANDA SCORZA, Yingxia WEN, Andrew GEALL, Frederick PORTER
  • Publication number: 20120237545
    Abstract: A combination of ultrafiltration and HPLC is used to analyze influenza virus. This combination is able to quantify hemagglutinin (HA) and correlates well with single radial immunodiffusion (SRID) results, but can be performed without the delay of waiting for immunochemical SRID reagents.
    Type: Application
    Filed: May 28, 2010
    Publication date: September 20, 2012
    Applicant: NORVARTIS AG
    Inventors: Philip Dormitzer, Yingxia Wen, Paola Rinella, Gene Palmer